IncobotulinumtoxinA for the Treatment of Glabella and Forehead Dynamic Lines: A Real-Life Longitudinal Case Series

Figures & data

Table 1 Main Demographic and Clinical Data of the Participants (n = 20)

Variables	Values
Sex, n (%)
Female	18 (90%)
Male	2 (10%)
Age, mean (SD)	38.4 (5.0)
Skin phototype, n (%)
II	6 (30%)
III	9 (45%)
IV	5 (25%)
Baseline MAS – Forehead Lines Dynamic, n (%)
I	3 (15%)
II	3 (15%)
III	3 (15%)
IV	11 (55%)
Units of IncobotulinumtoxinA at the forehead, mean (SD)	20.7 (7.3)
Points of injection at the forehead, mean (SD)	16.4 (4.0)
Baseline MAS – Glabella Lines Dynamic, n (%)
I	2 (10%)
II	8 (40%)
III	6 (30%)
IV	4 (20%)
Units of IncobotulinumtoxinA at glabella, mean (SD)	23.2 (4.6)
Points of injection at glabella, mean (SD)	5.6 (1.2)

Figure 1 Sequential visits (previous to 180 days) from a participant who received 23 units of IncobotulinumtoxinA on the glabella. Photos under maximum contraction.

Figure 2 Sequential visits (previous to 180 days) from a participant who received 22 units of IncobotulinumtoxinA on the forehead. Photos under maximum contraction.

Figure 3 Sequential visits (previous to 180 days) from a participant who received 44 units of IncobotulinumtoxinA on the forehead. Photos under maximum contraction.

Figure 4 MAS scores of dynamic lines of the forehead at D0, D15, D90, D120, and D180 (n = 20).

Figure 5 MAS scores of dynamic lines of the glabella at D0, D15, D90, D120, and D180 (n = 20).

Figure 6 Percent (95% CI) of participants with any improvement in forehead MAS dynamic lines severity, according to the visits (n = 20).

Figure 7 Percent (95% CI) of participants with any improvement in glabellar MAS dynamic lines severity, according to the visits (n = 20).